English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

The Coronavirus disease 2019 (COVID19) mass vaccination program in India began on January 16, 2021, with two vaccines: Covishield and Covaxin. One of the most important things to remember is that, while COVID-19 immunizations offer the highest protection, but do not stop us from catching the virus. It protects us from acquiring serious illnesses, lowers the possibility of hospitalization, and minimizes the risk of mortality. In many countries, including India, breakthrough infections in fully vaccinated persons have been observed. When a fully vaccinated individual contracts the SARs-COV-2 virus, it is known as a breakthrough infection. With a large population vaccinated, many breakthrough cases have come to the forefront. It is believed that vaccinated individuals either remain asymptomatic or develop mild to moderate symptoms. In certain cases, depending on the person’s age, pre-existing comorbidities, he or she may succumb to the virus. However, the chances are very rare. When we compared the data of breakthrough infection in terms of percentage, Covishield 22.16 percent, Covaxin 15.21 percent people got, but the disease was mild or asymptomatic.

Breakthrough infection in covid 19: Indian scenario